We hypothesized that the risk of AD and ADRD in those with hypertension at the time of cancer diagnosis who received angiotensin-II inhibiting antihypertensive medications would be higher than in those receiving angiotensin-II stimulating antihypertensive drugs. The gene discussed is AGT; the disease is cancer.